Cerebrolysin is not a single molecule. It is a mixture of low-molecular-weight peptides and free amino acids made by enzymatically breaking down purified pig (porcine) brain proteins. Roughly 75% of the preparation is free amino acids and about 25% is small biologically active peptide fragments, formulated as a sterile solution for injection. It is manufactured by EVER Pharma in Unterach, Austria, and catalogued in DrugBank as DB16599.
That makes it unusual for a site like this. Most compounds we cover are defined, synthetic peptides. Cerebrolysin is a biological extract with batch-to-batch variation baked into its nature, which matters when you get to the quality and testing discussion below.
Proposed mechanism
The stated idea is that Cerebrolysin's peptide fragments mimic the brain's own neurotrophic factors, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). Preclinical work attributes effects on neurogenesis, neuroplasticity, and protection against apoptosis to the mixture.
The honest caveat is that the specific molecular action is not pinned down. The Cerebrolysin entry on Wikipedia, drawing on the published literature, notes that its molecular effects "are not clear," and that some relevant peptides are short-lived in blood (the half-life of BDNF itself is around 10 minutes). So "mimics neurotrophic factors" is a hypothesis supported by lab data, not a settled fact.
What the clinical evidence shows
This is where claims and data part ways. Cerebrolysin has been studied for decades in stroke and dementia, and independent systematic reviews have repeatedly found the evidence thin.
- Acute ischaemic stroke. The 2023 Cochrane review by Ziganshina and colleagues (CD007026) pooled seven studies in 1,773 people. Moderate-certainty evidence indicated that adding Cerebrolysin (or the related agent Cortexin) to standard stroke therapy probably gives no benefit for preventing death from any cause. The review also flagged a possible higher rate of adverse events requiring hospitalization.
- Vascular dementia. The Cochrane review (CD008900) included six randomized trials with 597 participants. It found a measurable effect on cognition (standardized mean difference about 0.36) but rated the evidence as very low quality, with high risk of bias, and concluded that any real benefit "may be too small to be clinically meaningful." No new eligible trials had appeared since the prior version.
It is described as reasonably well tolerated in short-term use, but "tolerated" is not the same as "effective," and the better-designed reviews keep landing on weak or null results.
Regulatory status
Cerebrolysin is approved and prescribed in many countries, including Austria, Russia, China, South Korea, and across much of Eastern Europe and Asia, typically for stroke, dementia, and traumatic brain injury. It is not approved by the US FDA for any indication and has never been reviewed under a New Drug Application. In the US it has no legal status as a medicine. On the anti-doping side, Cerebrolysin is not a listed WADA substance, though athletes are responsible for anything they inject and growth-factor-adjacent products invite scrutiny.
The quality and testing angle
Because Cerebrolysin is a biological extract, identity and purity are harder to verify than for a defined peptide like, say, a single synthetic sequence. There is no simple "99% pure" number to chase. Material sold outside regulated channels as "research" Cerebrolysin carries the usual unknowns: what it actually contains, whether it matches the porcine-derived reference composition, and whether it is sterile. A certificate of analysis for a mixture like this is far less informative than for a single compound, and third-party raters that score vendors on COA transparency and independent testing can only do so much when the product itself is a complex extract.
None of this is medical, dosing, or efficacy advice. Materials discussed here are sold for research use only and are not approved for human consumption in the United States. The takeaway from the independent evidence is plain: the marketing outruns the data.